GSA Capital Partners LLP raised its position in TherapeuticsMD Inc (NASDAQ:TXMD) by 274.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,700 shares of the company’s stock after buying an additional 86,300 shares during the quarter. GSA Capital Partners LLP owned about 0.05% of TherapeuticsMD worth $573,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Stifel Financial Corp increased its holdings in TherapeuticsMD by 1.3% in the 1st quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock valued at $9,067,000 after buying an additional 23,141 shares during the period. Beaumont Financial Partners LLC bought a new position in TherapeuticsMD in the 1st quarter valued at about $123,000. New York State Common Retirement Fund grew its holdings in shares of TherapeuticsMD by 7.3% during the 1st quarter. New York State Common Retirement Fund now owns 255,339 shares of the company’s stock valued at $1,244,000 after purchasing an additional 17,400 shares during the last quarter. Iridian Asset Management LLC CT bought a new stake in shares of TherapeuticsMD during the 1st quarter valued at approximately $279,000. Finally, Cetera Advisors LLC grew its holdings in shares of TherapeuticsMD by 18.1% during the 1st quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock valued at $281,000 after purchasing an additional 8,800 shares during the last quarter. 72.70% of the stock is currently owned by hedge funds and other institutional investors.
Shares of TherapeuticsMD opened at $7.28 on Thursday, Marketbeat reports. The company has a market cap of $1.56 billion, a P/E ratio of -19.68 and a beta of 1.34. TherapeuticsMD Inc has a 1 year low of $4.34 and a 1 year high of $7.66.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, May 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. The business had revenue of $3.77 million for the quarter, compared to analyst estimates of $4.18 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The firm’s quarterly revenue was down 5.4% on a year-over-year basis. research analysts anticipate that TherapeuticsMD Inc will post -0.53 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the stock. BidaskClub lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, June 15th. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. Oppenheimer set a $12.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Tuesday, June 5th. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Tuesday, May 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of TherapeuticsMD in a report on Friday, June 15th. They set an “overweight” rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $14.63.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.